Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE trial

European Urology

Volumn 62, Issue 6, 2012, Pages 953-961

  Kader, A Karim ^a,b   Sun, Jielin ^a   Reck, Brian H ^c   Newcombe, Paul J ^d   Kim, Seong Tae ^a   Hsu, Fang Chi ^a   D'Agostino, Ralph B ^a   Tao, Sha ^a   Zhang, Zheng ^a   Turner, Aubrey R ^a   Platek, Greg T ^c   Spraggs, Colin F ^d   Whittaker, John C ^d   Lane, Brian R ^e   Isaacs, William B ^f   Meyers, Deborah A ^a   Bleecker, Eugene R ^a   Torti, Frank M ^a   Trent, Jeffery M ^g   McConnell, John D ^a   Zheng, S Lilly ^a   Condreay, Lynn D ^c   Rittmaster, Roger S ^c   Xu, Jianfeng ^a,g   more..

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e SPECTRUM HEALTH   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

AUC; Clinical trial; Detection rate; Genetics; Prospective study; Prostate cancer; Reclassification; SNPs

Indexed keywords

DUTASTERIDE;

ADULT; ARTICLE; CANCER RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; FALSE NEGATIVE RESULT; GENETIC MARKER; GENETIC RISK; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84868599480     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.05.006     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 229
2. J.C. Presti Jr. Repeat prostate biopsy - when, where, and how Urol Oncol 27 2009 312 314
3. L.T. Amundadottir, P. Sulem, and J. Gudmundsson A common variant associated with prostate cancer in European and African populations Nat Genet 38 2006 652 658
4. J. Gudmundsson, P. Sulem, and A. Manolescu Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 Nat Genet 39 2007 631 637
5. M. Yeager, N. Orr, and R.B. Hayes Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 Nat Genet 39 2007 645 649
6. J. Gudmundsson, P. Sulem, and V. Steinthorsdottir Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes Nat Genet 39 2007 977 983
7. D. Duggan, S.L. Zheng, and M. Knowlton Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP J Natl Cancer Inst 99 2007 1836 1844
8. G. Thomas, K.B. Jacobs, and M. Yeager Multiple loci identified in a genome-wide association study of prostate cancer Nat Genet 40 2008 310 315
9. J. Gudmundsson, P. Sulem, and T. Rafnar Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer Nat Genet 40 2008 281 283
10. R.A. Eeles, Z. Kote-Jarai, and G.G. Giles Multiple newly identified loci associated with prostate cancer susceptibility Nat Genet 40 2008 316 321
11. M. Yeager, N. Chatterjee, and J. Ciampa Identification of a new prostate cancer susceptibility locus on chromosome 8q24 Nat Genet 41 2009 1055 1057
12. J. Gudmundsson, P. Sulem, and D.F. Gudbjartsson Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility Nat Genet 41 2009 1122 1126
13. R.A. Eeles, Z. Kote-Jarai, and A.A. Al Olama UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study Nat Genet 41 2009 1116 1121
14. D.F. Easton, and R.A. Eeles Genome-wide association studies in cancer Hum Mol Genet 17 2008 R109 R115
15. S.L. Zheng, J. Sun, and F. Wiklund Cumulative association of five genetic variants with prostate cancer N Engl J Med 358 2008 910 919
16. J. Xu, J. Sun, and A.K. Kader Estimation of absolute risk for prostate cancer using genetic markers and family history Prostate 69 2009 1565 1572
17. C.A. Salinas, J.S. Koopmeiners, and E.M. Kwon Clinical utility of five genetic variants for predicting prostate cancer risk and mortality Prostate 69 2009 363 372
18. L.M. Fitzgerald, E.M. Kwon, J.S. Koopmeiners, C.A. Salinas, J.L. Stanford, and E.A. Ostrander Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features Clin Cancer Res 15 2009 3231 3237
19. G.A. Andriole, D. Bostwick, and O.W. Brawley The influence of dutasteride on the risk of biopsy-detectable prostate cancer: outcomes of the REduction by DUtasteride of Prostate Cancer Events (REDUCE) study N Engl J Med 362 2010 1192 1202
20. P.D. Pharoah, A.C. Antoniou, D.F. Easton, and B.A. Ponder Polygenes, risk prediction, and targeted prevention of breast cancer N Engl J Med 358 2008 2796 2803
21. S.T. Kim, Y. Cheng, and F.C. Hsu Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation Prostate 70 2010 1729 1738
22. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
23. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
24. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Statist Med 27 2008 157 172
25. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
26. A.J. Vickers, A.M. Cronin, E.B. Elkin, and M. Gonen Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers BMC Med Inform Decis Mak 8 2008 53
27. A.K. Kader, J. Sun, and S.D. Isaacs Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients Prostate 69 2009 1195 1205
28. J.B. de Kok, G.W. Verhaegh, and R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698
29. S.M. Aubin, J. Reid, and M.J. Sarno PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial J Urol 184 2010 1947 1952
30. S.A. Tomlins, S.M. Aubin, and J. Siddiqui Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA Sci Transl Med 3 2011 94ra72